MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling. - sprookjes - yvandenbroek - TriplyDB

MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

http://www.wikidata.org/entity/Q39393414

about

'Micro-managers' of hepatic lipid metabolism and NAFLD MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers microRNA regulation of Wnt signaling pathways in development and disease The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice MicroRNA-155 expression is independently predictive of outcome in chordoma.Extensive survey of STAT6 expression in a large series of mesenchymal tumors.Characterization of cancer stem-like cells derived from mouse induced pluripotent stem cells transformed by tumor-derived extracellular vesicles.EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.Advances in the targeted therapy of liposarcoma.Epigenetic regulation and functional characterization of microRNA-142 in mesenchymal cells.Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers.Epigenetic Regulators: New Therapeutic Targets for Soft Tissue Sarcoma.Deregulation of dicer and mir-155 expression in liposarcoma.The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma Key principles of miRNA involvement in human diseases Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.Targeting miR-155 to Treat Experimental Scleroderma MicroRNAs in common human diseases.Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma.Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein.Integrative transcriptome analysis identifies deregulated microRNA-transcription factor networks in lung adenocarcinoma.Inflammatory stress and sarcomagenesis: a vicious interplay.G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma.Molecular basis of the irritable bowel syndrome.Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis.MicroRNA-mediated gene regulations in human sarcomas.MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer.miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells.The multiple roles of microRNA-155 in oncogenesis.The pivotal role of microRNA-155 in the control of cancer.Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis.The microRNA regulatory network: a far-reaching approach to the regulate the Wnt signaling pathway in number of diseases.microRNAs and Soft Tissue Sarcomas.MiR-9-5p promotes MSC migration by activating β-catenin signaling pathway.

P2860

Q26801228-F00C23CF-7068-4A97-BE8F-EFDFCC38AFEB Q27006159-9F602AF7-6740-45E3-B527-53CF649C259D Q27011654-AE79CA3A-74B9-4DC4-98A0-DB7A87735C33 Q28076568-5356D02C-4111-43A2-A073-4DDE4181F8FF Q28087258-505814FC-957E-423B-A7EA-B4242B4DAA14 Q28389770-685CE221-15E5-484B-A285-DB09F1199BB0 Q33275600-62FC2A4F-68DA-43F6-B022-C9B45B0A4BCC Q33421985-0D9D5F15-DC8D-4377-971D-DD6C4F0A5BEA Q33935224-4224D846-6F5A-4CBF-90CB-D772B555565E Q34199631-324CEEC8-9368-4537-BBA8-085DC3CF8E1B Q34899627-07F10F5A-DB6A-47A0-91FD-04BFDDDCDB70 Q34952133-D279D6F9-3779-41E0-A6BA-6DC88BC93F4F Q35043761-064EBF1A-7E09-4D80-BFD9-7A755B4629EF Q35170116-9AF3DC1F-AFD0-48DC-B60F-D92C09874E68 Q35408800-59803F11-9296-42C7-A791-3D38466378AF Q35734256-F09ED602-47B1-4CB5-9CCF-4FB607DEB610 Q35833073-525403BE-6588-419C-85F5-A4C0609C9F78 Q35904618-165B0A5B-D827-4240-80C7-52234A6348B7 Q35990222-41037BF3-5899-42E2-B6DF-695791F752E2 Q36040449-B5428866-1807-44B3-9B42-AE18831B552D Q36297213-B5CE8B86-C46A-48ED-9F0D-3A06D7875C04 Q36524910-B6E0ACCE-13E2-42BE-BA07-D991CE24A107 Q36727816-7A4B2D76-0817-4F95-B8FA-D3545F8B6A67 Q36772110-A83D19C1-596B-46CE-99E3-4EFA7B918658 Q36878798-5806B532-C8D5-48F9-A361-F1F3B0C99B66 Q37074134-C916CE50-03D4-4C5C-8685-1A952E28588B Q37301705-0FAA4471-0911-4CFD-A00C-13DB7906B1B6 Q37378867-BDFF2BBE-11E9-4892-B114-FB4C11405986 Q37396062-FFF5D350-532B-4117-A86B-BE0B81D714EA Q37581343-9A01FFA0-6EEC-4DA4-8963-63842D5A61EC Q37701702-3E3BCE95-EE9E-4AAA-9B03-5FC40B201C7F Q38038076-3359F7DD-065F-4101-ACB6-4EE24FDD911E Q38095501-5D2E703E-4DD0-4B9D-BCD4-1AD273F1B1DF Q38096240-44F15A20-06B9-4A6A-B749-067FE2AEE4B3 Q38145349-BAB6D5A0-616C-4A56-A040-C0DD35B3D9B9 Q38152297-88D8558A-DC85-4ED4-B397-1D9A720EEE4B Q38259229-9BE0DF57-2B3D-41C8-A068-426E88E5C59B Q38622178-CB3C7D47-7AEA-4B98-84EB-2163CE0621BE Q38667023-BBBF969A-B776-426F-A95C-DF00E6E01654 Q38829769-142A965C-5616-44FA-811E-2A8B3E5403A3

P2860

MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

http://www.wikidata.org/entity/Q39393414

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

MiR-155 is a liposarcoma oncog ...... enhances β-catenin signaling.

@en

MiR-155 is a liposarcoma oncog ...... enhances β-catenin signaling.

@nl

type

label

MiR-155 is a liposarcoma oncog ...... enhances β-catenin signaling.

@en

MiR-155 is a liposarcoma oncog ...... enhances β-catenin signaling.

@nl

prefLabel

MiR-155 is a liposarcoma oncog ...... enhances β-catenin signaling.

@en

MiR-155 is a liposarcoma oncog ...... enhances β-catenin signaling.

@nl

P1433

Q39393414-93C78F25-6BA1-4F36-9CEC-521CFA857EFE

P1476

Q39393414-59DEA64B-1D3A-4ED4-9D37-1ED8AD743B4F

P2093

Q39393414-1DB22C66-F375-4E37-A631-FFF06EC56500

Q39393414-2567A1B1-AEE9-45EC-A692-812C8DBDC1E3

Q39393414-35326B73-8812-4967-8865-DCC29458F145

Q39393414-3A112915-288A-40B4-B2C7-5A4B0F45B87B

Q39393414-45BB61BA-8EA7-4C86-B013-6B0646BAB5EC

Q39393414-4A91C965-76FF-48EE-81E2-1AB1E8D1DAA3

Q39393414-7C7519EA-34A7-4B6E-9086-1A85BB183838

Q39393414-7F3B227B-4EA3-47B6-904B-40CF210D44C8

Q39393414-C0ECCA9F-630B-4E4C-8CAB-D28971E047F8

Q39393414-C3386210-B741-4232-9DD9-2833B875C87A

P2860

Q39393414-09A05FAB-9774-4DC5-BFD8-1AA8DE68EEB9

Q39393414-0C87A49F-06EE-4EC4-B7BA-F6B8A4307D9C

Q39393414-0D33A687-8488-49D2-8ACE-FC783C448BBC

Q39393414-12FEF2BB-D951-45E3-9A15-5CE26C222899

Q39393414-1312950E-53F4-46ED-BABA-C901A96FFDC0

Q39393414-1AF4AC85-AC4A-4A17-A419-D403BC8B6488

Q39393414-1DC5D7CB-DA06-4CFD-8C13-436AA6C0015F

Q39393414-23C45F2E-2B34-437F-8227-3FF2AA3E1EAC

Q39393414-25EF8A9A-D4C3-4739-AC28-068909C51FCB

Q39393414-316DA203-21C9-4E93-8CA7-656DA255ED79

P304

Q39393414-4F982503-528F-4EB9-8A69-1A3B3C84E110

P31

Q39393414-A5B05ADB-B013-42DF-969A-E32FB40EB197

P356

Q39393414-53CCD7CA-4E8D-4DC4-ADE5-807C241B2116

P407

Q39393414-CE7E6E41-C719-4A06-9182-C8CB0E03657D

P433

Q39393414-6F83D2FB-61D4-4E04-AA55-480EBA3A58D3

P478

Q39393414-56C86493-C8A4-4212-AAF2-313EC116A873

P50

Q39393414-29C0F37B-9B38-4BDF-91EC-B488B6166E42

Q39393414-2BCB90D0-E7A6-4FE8-BFF0-0F0BD1B0AC24

Q39393414-C56E02BA-843B-49D8-A0ED-992DF0876A7C

P577

Q39393414-2369E5F1-0B22-46B9-9BDC-B7714C97B1D0

P5875

Q39393414-703DB413-6C8A-434A-B0F6-B85B0906E5D5

P698

Q39393414-AA4CBD75-0A36-4639-8A2E-2F4B76403BF5

P932

Q39393414-D0F1BAED-E72D-41EC-9CC4-C963A696B301

P356

0008-5472.CAN-11-3027

P1433

Cancer Research

P1476

MiR-155 is a liposarcoma oncog ...... enhances β-catenin signaling.

@en

P2093

Aviad Hoffman

http://www.w3.org/2001/XMLSchema#string

Chad J Creighton

http://www.w3.org/2001/XMLSchema#string

Dina Lev

http://www.w3.org/2001/XMLSchema#string

Dolores Lopez Terrada

http://www.w3.org/2001/XMLSchema#string

Elizabeth G Demicco

http://www.w3.org/2001/XMLSchema#string

George G Calin

http://www.w3.org/2001/XMLSchema#string

Juehui Liu

http://www.w3.org/2001/XMLSchema#string

Katelynn Bill

http://www.w3.org/2001/XMLSchema#string

Pingyu Zhang

http://www.w3.org/2001/XMLSchema#string

Raphael E Pollock

http://www.w3.org/2001/XMLSchema#string

P2860

A microRNA expression signature of human solid tumors defines cancer gene targets

Accumulation of miR-155 and BIC RNA in human B cell lymphomas

MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer

Modulation of mismatch repair and genomic stability by miR-155

Wnt/beta-catenin signaling: components, mechanisms, and diseases

MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA

Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder

MicroRNA miR-155 is a biomarker of early pancreatic neoplasia

Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice

Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development

P304

1751-1762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-3027

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Alexander J. Lazar

Matthew L. Anderson

P577

2012-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221847691

http://www.w3.org/2001/XMLSchema#string

P698

22350414

http://www.w3.org/2001/XMLSchema#string

P932

3319789

http://www.w3.org/2001/XMLSchema#string